4:01 PM ET
10-Q
Financial Results
Inmune Bio Q3 2026 Results: Net Loss of $4.72M, Loss Narrows
For the nine months ended September 30, 2026, INmune Bio reported a net loss of $11.4 million, a significant reduction from the $40.7 million loss in the prior year period which included a $16.5 million impairment charge. The company reported zero revenue for the 2026 period and expressed substantial doubt about its ability to continue as a going concern due to insufficient liquidity to sustain operations for the next twelve months.
- Key figure
- Net loss $4.72M